Clinical trial data can be remarkably (and unnecessarily) difficult to read. Companies spin, short-sellers hawk, and everyone else is left swimming through the muck. But there is an art to reading scientific results — and you can learn it.

Subscribe to STAT Plus to join STAT national biotech columnist Adam Feuerstein and STAT senior science writer Sharon Begley for a special subscriber-only webinar on interpreting clinical trial data. They will share their recommendations on what to look for — and what not to fall for — when trying to make sense of the data. They’ll also walk through some case studies to help you prepare for the next big readout.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy